Oxaliplatin administration increases expression of the voltage-dependent calcium channel α2δ-1 subunit in the rat spinal cord

Journal of Pharmacological Sciences
Ken YamamotoKyoji Taguchi

Abstract

Oxaliplatin is a chemotherapeutic agent that is effective against various types of cancer including colorectal cancer. Acute cold hyperalgesia is a serious side effect of oxaliplatin treatment. Although the therapeutic drug pregabalin is beneficial for preventing peripheral neuropathic pain by targeting the voltage-dependent calcium channel α2δ-1 (Cavα2δ-1) subunit, the effect of oxaliplatin-induced acute cold hypersensitivity is uncertain. To analyze the contribution of the Cavα2δ-1 subunit to the development of oxaliplatin-induced acute cold hypersensitivity, Cavα2δ-1 subunit expression in the rat spinal cord was analyzed after oxaliplatin treatment. Behavioral assessment using the acetone spray test showed that 6 mg/kg oxaliplatin-induced cold hypersensitivity 2 and 4 days later. Oxaliplatin-induced acute cold hypersensitivity 4 days after treatment was significantly inhibited by pregabalin (50 mg/kg, p.o.). Oxaliplatin (6 mg/kg, i.p.) treatment increased the expression level of Cavα2δ-1 subunit mRNA and protein in the spinal cord 2 and 4 days after treatment. Immunohistochemistry showed that oxaliplatin increased Cavα2δ-1 subunit protein expression in superficial layers of the spinal dorsal horn 2 and 4 days after treatment...Continue Reading

References

Jul 2, 1999·Comparative Biochemistry and Physiology. Part C, Pharmacology, Toxicology & Endocrinology·R H ScottJ Mordue Luntz
Jan 24, 2002·Neuropharmacology·Klaus FinkManfred Göthert
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Oct 1, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Chun-Ying LiZ David Luo
Jan 24, 2006·The Journal of Pain : Official Journal of the American Pain Society·Tony L Yaksh
May 12, 2006·The Journal of Pharmacology and Experimental Therapeutics·Misaki MatsumotoHiroshi Ueda
Nov 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Mark J FieldDic Williams
Dec 5, 2006·Seminars in Cell & Developmental Biology·Valentin K Gribkoff
Jan 16, 2007·Trends in Pharmacological Sciences·David J DooleyDouglas Feltner
Apr 3, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Claudia S BauerAnnette C Dolphin
Feb 6, 2010·Journal of Neurochemistry·Naresh KumarTerence J Coderre
Oct 24, 2012·Journal of Pharmacological Sciences·Kazuyoshi KawakamiKyoji Taguchi
Feb 2, 2013·Biological & Pharmaceutical Bulletin·Manahito AokiKunio Ishii
Feb 5, 2013·The Journal of Pain : Official Journal of the American Pain Society·Ye CaoBarry J Sessle

❮ Previous
Next ❯

Citations

Sep 22, 2017·Frontiers in Molecular Neuroscience·Jennifer R DeuisIrina Vetter
Apr 23, 2017·Current Pain and Headache Reports·Kathleen MeachamSimon Haroutounian
Jan 28, 2021·Journal of Applied Oral Science : Revista FOB·Nattapon RotpenpianAree Wanasuntronwong
Jan 29, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Kinga SałatRobert Sałat
Apr 4, 2021·Cancers·Manaal SiddiquiDietrich Büsselberg
Aug 19, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Anna FurgałaKinga Sałat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.